Abilify MyCite and Metoclopramide Orally Disintegrating Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using metoclopramide together with ARIPiprazole is not recommended. Treatment with either medication alone can cause Parkinson-like symptoms and abnormal muscle movements, and combining them may increase that risk. The most serious of the movement disorders associated with the use of these medications is a condition known as tardive dyskinesia (TD). TD mostly involves muscles in the face, but may also involve those in the limbs. You cannot control these movements, and they may not go away even after stopping the medications. There is no treatment for TD, but symptoms may lessen or disappear over time after stopping the medications. You may be more likely to develop TD if you are elderly, especially if you are a woman, or if you have diabetes. Your risk also increases the longer you take these medications and the more of each you take. As such, treatment with metoclopramide should generally be limited to 12 weeks. Let your doctor know promptly if you experience muscle spasm or movements that you can't stop or control, such as lip smacking, chewing, puckering, frowning or scowling, tongue thrusting, teeth clenching, jaw twitching, blinking, eye rolling, shaking or jerking of arms and legs, tremor, jitteriness, restlessness, pacing, and foot tapping. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

CONTRAINDICATED: Coadministration of metoclopramide with phenothiazines, neuroleptics, or other antidopaminergic agents (e.g., tetrabenazine) may increase the frequency and severity of extrapyramidal reactions (i.e., acute dystonic reactions, tardive dyskinesia, akathisia, Parkinson-like symptoms) due to additive antidopaminergic effects. By itself, metoclopramide can cause acute dystonic reactions in approximately 0.2% of patients treated with the usual adult dosages of 30 to 40 mg/day. These reactions are typically seen during the first 24 to 48 hours of treatment, occur more frequently in pediatric and adult patients less than 30 years of age, and are increased with higher dosages. Symptoms may include involuntary movements of limbs, facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, opisthotonus (tetanus-like reactions), and rarely, stridor and dyspnea due to laryngospasm. Dystonic reactions usually respond to treatment with anticholinergic agents such as diphenhydramine or benztropine. Tardive dyskinesia (TD) is a potentially irreversible and disfiguring disorder characterized most frequently by involuntary movements of the tongue, face, mouth, or jaw, and less frequently by involuntary movements of the trunk and/or extremities. Movements may be choreoathetotic in appearance. Although the risk of TD with metoclopramide has not been extensively studied, a prevalence of 20% has been reported in one study among patients treated for at least 12 weeks. The risk is increased in the elderly, women, and diabetic populations; however, it is not possible to predict which patients will develop TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose. There is no known effective treatment. In some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn. Akathisia, or motor restlessness, consist of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, and foot tapping. Symptoms may disappear spontaneously or respond to a reduction in dosage. Parkinsonian-like symptoms may include bradykinesia, tremor, cogwheel rigidity, and mask-like facies. These symptoms most commonly occur within the first 6 months of metoclopramide therapy and subside within 2 to 3 months following drug discontinuation.

MANAGEMENT: Due to the potential for increased risk of serious and potentially irreversible extrapyramidal reactions, metoclopramide should not be prescribed in combination with other antidopaminergic agents. In addition, metoclopramide should not be used for longer than 12 weeks except in rare cases where therapeutic benefit is anticipated to outweigh the risk of developing tardive dyskinesia.

Abilify MyCite

Generic Name: aripiprazole

Brand name: Abilify MyCite, Abilify, Abilify Discmelt, Abilify Maintena, Aristada, Aristada Initio

Synonyms: Abilify Mycite

What is Abilify MyCite?

Metoclopramide Orally Disintegrating Tablets

Generic Name: metoclopramide

Brand name: Metozolv ODT, Reglan

Synonyms: Metoclopramide

What is Metoclopramide Orally Disintegrating Tablets?